Want to see IN:ONESOURCE full AI Analyst Report?
ONESOURCE Stock Chart & Stats
₹1540.35
--
Market closed
₹1540.35
--
Day’s Range― - ―
52-Week Range₹1,075.00 - ₹2,082.10
Previous CloseN/A
VolumeN/A
Average Volume (3M)3.94K
Market Cap
₹193.45B
Enterprise Value₹199.46B
Total Cash (Recent Filing)₹1.80B
Total Debt (Recent Filing)₹12.95B
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Aug 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)9.53
Shares Outstanding114,645,800
10 Day Avg. Volume3,856
30 Day Avg. Volume3,937
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.89
Price to Sales (P/S)11.87
P/FCF Ratio-24.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)38.15
Revenue Forecast (FY)₹22.08B
Bulls Say, Bears Say
Bulls Say
Strong FY2026 Revenue GrowthA ~77% revenue surge in FY2026 reflects meaningful top-line momentum and growing commercial traction. Sustained revenue expansion provides a base to absorb costs, supports scale economics, and can enable future margin recovery if management converts product demand into higher-margin sales and tighter cost control.
Relatively Low Historical LeverageA historically low debt-to-equity (~0.16 in FY2025) and a sizeable equity base give the company financial flexibility to fund operations or investment without immediate refinancing stress. This balance-sheet capacity can absorb near-term volatility and supports strategic options while turnaround efforts proceed.
Operational Scale (headcount)A workforce of ~1,412 indicates meaningful operational, manufacturing and commercial capability for a specialty pharma company. This scale supports product development, regulatory processes, distribution and customer service, which are durable advantages in biotech requiring complex execution to sustain growth over time.
Bears Say
Negative Operating And Free Cash FlowSustained negative operating and free cash flow across two years, worsening in FY2026, signals persistent cash burn and that operations do not yet self-fund. This structural cash shortfall forces reliance on external financing, increases dilution or leverage risk, and constrains the firm’s ability to invest or weather shocks.
Sharp Profitability DeteriorationA transition from near breakeven to a large FY2026 net loss and sharply weaker EBIT shows margins under stress. If cost structure or product mix issues persist, the business may not convert revenue growth into sustainable profits, undermining long-term viability and operational reinvestment capacity.
Rising Debt Amid LossesIncreasing debt concurrent with a move to negative profitability raises leverage and refinancing risk. Higher obligations while cash generation is weak can pressure covenants or force dilutive capital raises; this combination erodes financial flexibility and elevates execution risk over the medium term.
OneSource Specialty Pharma Limited News
ONESOURCE FAQ
What was OneSource Specialty Pharma Limited’s price range in the past 12 months?
OneSource Specialty Pharma Limited lowest stock price was ₹1075.00 and its highest was ₹2082.10 in the past 12 months.
What is OneSource Specialty Pharma Limited’s market cap?
OneSource Specialty Pharma Limited’s market cap is ₹193.45B.
When is OneSource Specialty Pharma Limited’s upcoming earnings report date?
OneSource Specialty Pharma Limited’s upcoming earnings report date is Aug 10, 2026 which is in 36 days.
How were OneSource Specialty Pharma Limited’s earnings last quarter?
OneSource Specialty Pharma Limited released its earnings results on May 13, 2026. The company reported ₹0.4 earnings per share for the quarter, the consensus estimate of ₹0.4 by ₹0.
Is OneSource Specialty Pharma Limited overvalued?
According to Wall Street analysts OneSource Specialty Pharma Limited’s price is currently Overvalued.
Does OneSource Specialty Pharma Limited pay dividends?
OneSource Specialty Pharma Limited does not currently pay dividends.
What is OneSource Specialty Pharma Limited’s EPS estimate?
OneSource Specialty Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OneSource Specialty Pharma Limited have?
OneSource Specialty Pharma Limited has 114,645,800 shares outstanding.
What happened to OneSource Specialty Pharma Limited’s price movement after its last earnings report?
OneSource Specialty Pharma Limited reported an EPS of ₹0.4 in its last earnings report, expectations of ₹0.4. Following the earnings report the stock price went down -2.34%.
Which hedge fund is a major shareholder of OneSource Specialty Pharma Limited?
Currently, no hedge funds are holding shares in IN:ONESOURCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
OneSource Specialty Pharma Limited
OneSource Specialty Pharma Limited is a biopharmaceutical company focused on the discovery, advancement, production, and market introduction of biological drug products, primarily offered in diverse injectable formulations. The company conducts its operations internationally, with a footprint in India, Ireland, and the United States. It delivers comprehensive contract development and manufacturing (CDMO) services for biologics, encompassing all phases from preclinical and clinical development to commercial-scale supply. Its offerings extend to integrated drug-device systems such as pre-filled syringes, various pen injectors (including dial, push, and pull-push types for both variable and fixed doses), and autoinjectors. Furthermore, OneSource Specialty Pharma manufactures sterile injectable drugs and soft gelatin capsules, and provides specialized biologics solutions tailored for microbial and mammalian cell-line biopharmaceuticals, as well as for cell, gene, and RNA therapies. Established in 2007, the company, headquartered in Bengaluru, India, was formerly known as Stelis Biopharma Limited until its rebranding in February 2024.
Technical Analysis
Alembic Pharmaceuticals Limited
―
AstraZeneca Pharma India Limited
―
Eris Lifesciences Ltd
―
PFIZER LIMITED
―
Piramal Pharma Limited
―